Estudo randomizado | Desfechos similares para o tratamento de 5 ou de 2 anos com zoledronato após quimioterapia adjuvante no câncer de mama inicial.

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer – The ASCO Post

Estudo original: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)